Abstract
Previously, we prepared lipid emulsions with soybean oil (SO; 20%) as oil phase and hydrogenated castor oils (HCOs; 2.4%) as emulsifiers (SO(20)/HCOs(2.4)), and found that the lipid emulsions prepared with HCO of 10 oxyethylene units (SO(20)/HCO10(2.4)) were quickly cleared from the plasma, while those prepared with HCO of 20 oxyethylene units (SO(20)/HCO20(2.4)) showed prolonged plasma circulation of the incorporated drug (Ueda et al., 2003) . In the present study, the pharmacokinetics of menatetrenone incorporated into SO/HCO10s and SO/HCO20s of different particle sizes (100-280 nm), obtained by altering the SO contents, were examined in rats. The plasma half-lives of menatetrenone as SO/HCO10s were similar to each other, irrespective of particle size, even though the liver uptake of menatetrenone as SO(2.5)/HCO10(2.4) was larger than that as SO(20)/HCO10(2.4). The menatetrenone half-lives were also similar to each other for SO/HCO20s. The pretreatment with dextran sulfate 500,000 (DS500), a suppressor of the reticuloendothelial system (RES), increased the plasma concentration and inhibited the liver uptake of menatetrenone as SO/HCO10s, but not for those as SO/HCO20s. These findings indicated that the particle sizes did not affect the minimum oxyethylene units within HCOs for the prolonged plasma circulation of menatetrenone as SO/HCOs, which was 20.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call